Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. (NASDAQ: ADTX) is an innovative life sciences company specializing in the development and commercialization of immune monitoring and modulation technologies. The company's mission is to advance humanity into the 'age of immunity' by decoding and harnessing the immune system for better health outcomes.
Aditxt's portfolio includes two flagship programs: Adimune™ and AditxtScore™. Adimune™ is focused on creating immunotherapies that promote tolerance to transplanted organs, while AditxtScore™ offers advanced immune monitoring solutions. The company's products and technologies aim to address critical medical needs, such as preventing organ transplant rejection, managing autoimmune diseases, and providing personalized diagnostic insights.
Recently, Aditxt has expanded its reach by acquiring strategic assets and forming new partnerships. Notably, its subsidiary Pearsanta, Inc. acquired MDNA Life Sciences’ proprietary early disease and cancer detection platform, including Mitomic™ technology. This acquisition enhances Aditxt's capabilities in precision diagnostics and early disease detection, with applications spanning various cancers and other serious health conditions.
Financially, Aditxt has shown robust growth through strategic acquisitions and innovative product development. The company’s commitment to enhancing patient outcomes through cutting-edge technologies is evident in its expanding product line and growing market presence.
For more information, visit the official website at aditxt.com.
Aditx Therapeutics (Nasdaq: ADTX) announced the appointment of Dr. Dolly B. Tyan as Senior Vice President of Clinical Development – Transplantation. Dr. Tyan will spearhead the company's organ rejection therapeutic program, advancing candidates toward clinical trials and developing new products. She brings over 45 years of experience in transplantation, having contributed to landmark technologies in the field. Her initial focus will be on Aditxt's Apoptotic DNA Immunotherapy™ (ADi™) for skin allografts. Aditxt aims for breakthroughs in organ acceptance and reducing transplant rejection.
Aditx Therapeutics (ADTX) announced a financing deal with an institutional investor, projected to net approximately $4.5 million. This funding aims to enhance the AditxtScore™ immune monitoring service and support general corporate needs. The investor will purchase a $6.0 million convertible promissory note, convertible at $4.00 per share, with repayments starting in July 2021. Additionally, Aditx raised $3.3 million from warrant exercises. CEO Amro Albanna emphasized that this funding will help meet the growing demand for immune monitoring services amid rising COVID-19 cases.
Aditx Therapeutics (ADTX) announced the launch of the AditxtScore™ Immune Monitoring Platform effective February 1, 2021. This platform includes AditxtScore™ for COVID-19, designed to assess an individual's infection and immunity status against SARS-CoV-2. The test will evaluate the virus's presence and measure antibody levels for neutralization. Aditxt plans to offer this as a Lab Developed Test (LDT) through CLIA-certified reference labs, enabling channel partners to efficiently integrate the service without extra resources.
Aditxt Therapeutics has announced a distribution agreement with Todos Medical for its AditxtScore™ for COVID-19. This service, which aims to monitor immunity against SARS-CoV-2, is expected to be available in January 2021. Todos Medical will manage blood sample collection and processing at Aditxt's CLIA-accredited center. AditxtScore™ will evaluate both antibody and neutralizing antibodies, with plans to expand into T-cell and B-cell assessments, making it a comprehensive immune profiling tool as vaccine rollouts increase. This agreement marks a significant commercial step for Aditxt.
Aditxt Therapeutics, a life sciences company focused on enhancing immune system health, will present at the 13th annual LD Micro Main Event on December 15, 2020, at 11:00 AM EST. CEO Amro Albanna will address a live audience in a virtual format, featuring a distinctive Q&A session with investors. The event, taking place on the Sequire Virtual Events platform, aims to deliver an engaging experience for both executives and investors. Aditxt is developing biotechnologies for immune monitoring and reprogramming, targeting issues like organ rejection and autoimmune diseases.
Aditxt Therapeutics, Inc. (ADTX), a company focused on immune system health, announced a review of data from its AditxtScore™ for COVID-19 by Dr. Drew Pinsky and CEO Amro Albanna. This event is part of an ongoing clinical study measuring immunity against COVID-19. The AditxtEngage™ event is set for December 1, 2020, and will stream live from the AditxtScore™ Center. Aditxt is developing technologies aimed at immune monitoring and reprogramming, addressing issues like organ rejection and autoimmune diseases. For more details, visit Aditxt's website.
Aditx Therapeutics, Inc. (Nasdaq: ADTX) has appointed Anthony Voorhies as Head of Business Development for AditxtScore™, enhancing its immune monitoring platform. Voorhies brings extensive experience in diagnostics and medical devices, having previously worked with Calroy Health Sciences and Itamar Medical. CEO Amro Albanna anticipates Voorhies' leadership will propel AditxtScore toward proactive immune diagnosis. Aditxt focuses on technologies to improve immune health, including personalized immune profiling and immune system reprogramming.
Aditx Therapeutics (Nasdaq: ADTX) has announced that its AditxtScore™ laboratory operations for immune monitoring have received CLIA certification, enabling the launch of AditxtScore™ for COVID-19 as a Laboratory Developed Test (LDT). The operations will be co-located with Salveo Diagnostics in Richmond, VA, facilitating a targeted commercial launch in January 2021. Aditxt is also pursuing Emergency Use Authorization (EUA) from the FDA for AditxtScore™, anticipated to lead to 510(k) clearance. CEO Amro Albanna emphasized the need for ongoing immune monitoring with new vaccines coming to market.
Aditx Therapeutics (Nasdaq: ADTX) provided a business update following its Form 10-Q filing. The company successfully completed its IPO and follow-on offering, now holding $13.7 million in cash as of September 30, 2020. Key developments include the introduction of the AditxtScore™ Monitoring platform for COVID-19 antibody detection, pending FDA Emergency Use Authorization. Aditxt aims to enhance immune health through innovative technologies, focusing on personalized immune monitoring and pre-clinical immune reprogramming.
Aditxt Therapeutics, Inc. (Nasdaq: ADTX) announces the launch of AditxtEngage™, a new platform for investor engagement. The first event will take place on October 6, 2020, at 4:30 PM ET, featuring CEO Amro Albanna and moderated by Chris Lahiji of LD Micro. This initiative aims to inform stakeholders about the company’s growth and development, focusing on its biotechnologies for immune system health. Aditxt is known for its immune monitoring and reprogramming technologies, currently in the pre-clinical stage.
FAQ
What is the current stock price of Aditxt (ADTX)?
What is the market cap of Aditxt (ADTX)?
What is Aditxt, Inc.'s core business?
What are the main products offered by Aditxt?
What recent acquisitions has Aditxt made to enhance its capabilities?
What is the significance of Aditxt's Adimune™ program?
How does AditxtScore™ contribute to the company's mission?
What is Mitomic™ technology, and how does it benefit Aditxt?
What financial achievements has Aditxt made recently?
Who are Aditxt's target customers?
How does Aditxt's strategic acquisition align with its mission?